Wide-ranging ramifications of China’s new price regulation
This article was originally published in SRA
Newly introduced controls on the retail prices of basic drugs sold in China will have broad implications for existing sales, distribution, retail and supply arrangements, say lawyers at an Australian law firm familiar with the Chinese pharmaceutical market. The lawyers, from Allens Arthur Robinson, which has offices in China, advise that the commercial basis and contractual terms for such arrangements should be carefully reviewed1.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Hikma has received another setback on its US application for a generic version of Advair following a minor complete response letter from the FDA. The resulting delay will push back the expected final response date from the agency closer to that expected by rival Cipla, which filed an ANDA earlier this year.
The AAM has published a timely guide highlighting various voter issues of concern in the run-up to the US elections, including anti-competitive tactics building on monopoly pricing and weak patent laws. The AAM has also called for policies to encourage generic and biosimilar entry in the market while the guide also focuses on policies around the US supply chain.